🇯🇵·6h agoIndustry
エンスプリング、国内初の「MOG抗体関連疾患の再発予防」治療薬として適応拡大申請
Publisher
C
Chugai Pharmaceutical News
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical News
- Region
- Japan
- Scope
- Industry
- Published
- July 31, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Related coverage
More related coverage
Recordati/5h ago
Press release (on il Sole 24 Ore) – Interim Report First Half (as at 30 June 2026)
Chugai Pharmaceutical/6h ago
Chugai Files for Additional Indication of Enspryng as Japan’s Potential First Treatment for Prevention of Relapse in MOG Antibody-associated Disease
Natco Pharma/12h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/12h ago